Question · asked by 1 review

Summary of findings ‐ Inhaled mannitol vs dornase alfa: HRQoL ‐ all domains (change from baseline) Scale: age‐appropriate versions of the CFQ‐R questionnaire

Population
children and young adults with CF
Intervention
Summary of findings ‐ Inhaled mannitol
Comparison
dornase alfa
Outcome
HRQoL ‐ all domains (change from baseline) Scale: age‐appropriate versions of the CFQ‐R questionnaire

What each review found

Include earlier review versions
FindingEffectStudiesGRADE certainty
Summary of findings ‐ Inhaled mannitol vs dornase alfa
HRQoL ‐ all domains (change from baseline) Scale: age‐appropriate versions of the CFQ‐R questionnaire · children and young people with CF
Inhaled mannitol for cystic fibrosis (2020) · Cochrane Headline outcomes only
no estimate extracted231 participantsVery low

Findings are shown side by side, never pooled across reviews.

The reviews

ReviewSearched up toIncluded studiesAMSTAR 2
Inhaled mannitol for cystic fibrosis
2020 · Cochrane Headline outcomes only
Not reportedNot extractedNot assessed

The same intervention and outcome, asked in another population or against another comparator.

How reviews are matched to this question

Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.